Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
David S Kabakoff is Director at Nextcure. OQRO lists 1 transaction filed with the SEC under this name, the latest on Jun 22, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
NextcureNXTC
Jun 18, 20263,510disclosed Jun 22
DetailsOfficial recordDavid S Kabakoff bought shares on the open market in 2019, and has not bought since 2019. Sales in 3 of the 8 years since 2019.
In SEC filings since 2019: the latest open-market purchase is from 2019; the latest open-market sale is from 2021.
Castle Biosciences (CSTL), from 2019 to 2021: 1 purchase and 38 sales.
David S Kabakoff bought shares on the open market in 2019, and has not bought since 2019. Sales in 3 of the 8 years since 2019.
David S Kabakoff reported 1 open-market purchase and 38 sales since 2019; purchases in 2019.
| Year | Bought | Sold |
|---|---|---|
| 2021 | — | $26.2M15×15 trades |
| 2020 | — | $38.2M22×22 trades |
| 2019 | $1M1×1 trade | $1441×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
David S Kabakoff reported 1 open-market purchase and 38 sales here, 2019 to 2021.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
